Related Experiment Videos
Hormonal therapy: historical perspective to future directions
1Urologic Oncology Clinic, Urology Service, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA. david.mcleod@na.amedd.army.mil
Urology
|April 2, 2003
Summary
Hormonal therapies for prostate cancer, including estrogens and LHRH agonists, suppress testosterone. While effective, side effects and optimal use in early stages require further investigation for improved survival benefits.
Area of Science:
- Oncology
- Endocrinology
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Hormonal therapy aims to suppress testosterone production.
Observation:
- Estrogen therapy was an early hormonal treatment but had side effects.
- Luteinizing hormone-releasing hormone (LHRH) agonists were introduced in the 1980s.
- Parenteral estrogen administration may reduce side effects.
Findings:
- LHRH agonists reduce testosterone to castration levels within weeks, but can cause tumor flare.
- Antiandrogen monotherapy may improve quality of life compared to androgen deprivation.
- Combined androgen blockade benefits are still under investigation.
Implications:
- Hormonal therapy may offer survival benefits when started earlier in prostate cancer.
- Estrogen therapy is being revisited due to potential for modulated side effects.
- Future research will focus on optimizing hormonal therapy regimens for efficacy.